ArticleEpilepsia2026
Targeted senotherapy improves electrographic and behavioral outcomes in a mouse model of temporal lobe epilepsy.
Article in Epilepsia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectiveCurrent pharmacotherapy for temporal lobe epilepsy (TLE) is limited to symptomatic treatment and leaves approximately one third of patients with inadequate seizure control. Discovering disease-modifying targets is an unmet clinical need. We have previously identified senescent cells (SCs) as one such target. Many drugs that eliminate SCs (senolytics) interfere with apoptotic resistance proteins, potentially resulting in broad cytotoxicity and numerous side effects. Newer, more targeted therapies, like selective senescence killing compound 1 (SSK1), a gemcitabine prodrug that is selectively activated in SCs, offer the possibility to reduce off-target effects, but SSK1 has yet to be investigated in any preclinical epilepsy model.
methodsWe used pilocarpine to induce status epilepticus (SE) in 3- to 4-month-old mice. Immediately following SE, mice were randomly assigned to receive either SSK1 treatment or vehicle for the remainder of the study. We assessed behavioral performance on memory tasks, seizure burden by EEG, and histological markers of SCs.
resultsSE robustly increased hippocampal and thalamic expression of SC marker p16 by over 100% compared to saline controls. SSK1 treatment reduced p16+ cells by ~45%, without any apparent neurotoxicity. In addition, SSK1 treatment normalized spatial memory impairments and reduced spontaneous seizure burden, completely protecting a majority (60%) of animals from seizures. SC burden in the hippocampus, but not the thalamus, correlated with seizure burden in vehicle-treated animals. SIGNIFICANCE: These findings lend further credence to the viability of targeting SCs to treat TLE. As with other genetic and pharmacologic SC ablation strategies, SSK1 produced a similar reduction in p16+ cells and normalization of spatial memory. SSK1, however, displays a stronger protective effect against seizures. In short, SSK1 is a compelling, translationally viable option for senolysis in TLE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.